On June 16, 2026, stockholders approved three proposals: the issuance of shares upon the exercise of warrants (including those exceeding 19.99% of outstanding common stock as of April 22, 2026) at an exercise price of $0.00001 per share, the adjustment of the number of shares issuable upon warrant exercise, and voluntary adjustments to the warrant exercise price. The company operates in the biopharmaceutical industry and develops therapeutic products.

Aspire Biopharma Holdings, Inc. entered into a purchase agreement with FireFish TopCo, LLC to acquire all equity interests in certain subsidiaries and all assets of other business entities. The transaction involves a base purchase price of $30,000,000 plus $800,000 for deferred revenue, adjusted for tax obligations and indebtedness. The acquisition targets automotive systems businesses, specifically driver control systems in the Czech Republic and the United States. Aspire Biopharma Holdings, Inc. operates in the automotive technology sector, focusing on electronic driver control and vehicle electrification and sustainability systems.